Brain aging is the critical and common factor among several neurodegenerative disorders
and dementia. Cellular, biochemical and molecular studies have shown intimate links …

Epigenetic mechanisms, which include DNA methylation, a variety of post-translational
modifications of histone proteins (acetylation, phosphorylation, methylation, ubiquitination …

Hydroxamate‐based histone deacetylase inhibitors (HDACIs) have been approved as
therapeutic agents by the US Food and Drug Administration for use in oncology …

Alzheimer's disease (AD) represents a particular therapeutic challenge because its
aetiology is very complex, with dynamic progression from preclinical to clinical stages …

Central nervous system (CNS) neurodegenerative diseases are characterized by faulty
intracellular transport, cognition, and aggregate regulation. Traditionally, neuroprotection …

HDAC inhibitors have been reported to produce antidepressant and pro-cognitive effects in
animal models, however, poor brain bioavailability or lack of isoform selectivity of current …

We perform a large-scale meta-analysis of 51 peer-reviewed 3xTg-AD mouse publications
to compare Alzheimer's disease (AD) quantitative clinical outcome measures, including …

Small guanosine triphosphatases (GTPases) of the Ras superfamily are key regulators of
many key cellular events such as proliferation, differentiation, cell cycle regulation …

Modulation of gene expression is a constant and necessary event for mammalian brain
function. An important way of regulating gene expression is through the remodeling of …

Alzheimer's disease (AD) is one of the most common neurodegenerative disorders, which is
characterized by the primary risk factor, age. Several attempts have been made to treat AD …